A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
Key facts
- Who runs it
- University of Iowa
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 3 people enrolled
- Started
- 7 Jul 2022
- Ended
- 24 Nov 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Niraparib
- Dostarlimab
- Short course radiation
- Record updated
- 29 June 2026
- Why it stopped
- Toxicity in phase 1
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 44 criteriaShow less
Who can take part
- Ability to understand and willingness to provide independent informed consent; legally authorized representative consent and/or power-of-attorney is not allowed
- Age at least 18 years at the time of study drug administration
- Resectable locally advanced rectal cancer (i.e., T3 to T4 or T1-T4 with N1-2 M0)
- Recommended to receive total neoadjuvant therapy consisting of preoperative radiation therapy followed by systemic FOLFOX chemotherapy
- Adequate performance status (ECOG of 0 or 1; or KPS of >70)
- Agree to adhere to lifestyle considerations throughout study duration
- Agree to not donate blood during the study or for 90 days after the last dose of study treatment
Who cannot take part
- Prior pelvic radiotherapy
- Indication for total neoadjuvant therapy or alternative radiation regimen
- Recommended to receive a chemotherapy regimen other than FOLFOX chemotherapy. CapeOX (oral xeloda plus oxaliplatin) is an acceptable alternative as it contains the core fluoropyrimidine + oxaliplatin backbone
- Indication for alternative radiation dose or fractionation regimen
- Prior anti-PD-L1 therapy, PARPi therapy, or known germline BRCA-1/2 mutation as patients with germline BRCA-1/2 mutations have an increased risk of severe normal tissue injury to combination radiation and PARP inhibition
- Received a live vaccine within 14 days of initiating protocol therapy
- Received colony stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior to Day 1 of protocol therapy
- Major surgery within 3 weeks prior to Day 1 of protocol therapy (participant must recover from any surgical effects)
- Investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to Day 1 of protocol therapy
- Known grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment
- Diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)
- Known history of ≥ grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities
- Diagnosis of immunodeficiency or has received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy
- Uncontrolled arterial hypertension, i.e. systolic BP > 140 mmHg, diastolic BP > 90 mmHg
- Active Crohn's disease or another inflammatory bowel disease
- Any T or N stage disease that is deemed unresectable by colorectal surgery without neoadjuvant therapy
- Known hypersensitivity to niraparib and dostarlimab components or excipients
- Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
- Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)
- Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- History of interstitial lung disease
- Active or uncontrolled infection necessitating hospitalization or treatment delay
- Known serious, uncontrolled medical disorder or nonmalignant systemic disease that preclude eligibility to undergo low anterior resection (LAR). Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, or any psychiatric disorder that prohibits obtaining informed consent
- Absolute neutrophil count < 1,500 cells /µL
- Platelets < 100,000 cells/µL
- Hemoglobin <9 g/dL
- Serum creatinine > 1.5 x upper limit of normal (ULN) or calculated creatinine clearance 60mL/min using the Cockcroft-Gault equation
- Total bilirubin > 1.5 x ULN (>2.0 x ULN in patients with known Gilberts syndrome) or direct bilirubin > 1 x ULN
- Aspartate aminotransferase and alanine aminotransferase > 2.5 x ULN
- International normalized ratio (INR) or prothrombin time (PT) >1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants
- Activated partial thromboplastin time (aPTT) >1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- Platelet transfusion ≤ 4 weeks prior to initiating protocol therapy
- Patients with known HIV who have documented detectable viral load or patients with a documented undetectable viral load and a CD 4 count < 350 cells within 6 months of study treatment day
- Pregnancy. Participant must have a negative serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees use a highly effective method of contraception from screening through 180 days after the last dose of niraparib and after the last dose of dostarlimab, or is of nonchildbearing potential. Nonchildbearing potential is defined as follows (by other than medical reasons):; ≥ 60 years of age; Post-hysterectomy. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound
- Presence of any M1 metastatic lesions
- Actively breastfeeding. Participant must agree to not breastfeed during the study or for 8 weeks after the last dose of study treatment
- Declines to use a highly effective method of contraception (see Section 5.2.1 for a list of acceptable birth control methods). Eligible patients must agree to highly effective methods of contraception starting with the first dose of study treatment through 180 days after the last dose of niraparib and dostarlimab
Where in United States
- Holden Comprehensive Cancer Center at the University of IowaIowa City, United States
About the trial
What the trial wants to find out
This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures.
The 2 groups in the trial
- Cohort 1 (starting)Treatment being tested
niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
Treatment: Niraparib, Dostarlimab, and Short course radiation
- Cohort 2Treatment being tested
niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
Treatment: Niraparib, Dostarlimab, and Short course radiation
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b/2 Trial of Preoperative Niraparib, Dostarlimab, and Hypofractionated Radiotherapy for the Treatment of Locally-advanced Rectal Cancers.
- Record updated
- 29 June 2026